Insight on Therapy Area in North America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Brief
Brief

Brief: Hepatitis C/AASLD 2010

This brief is an overview of the HCV highlights from the 2010 American Association of the Study of Liver Disease meeting. It discusses pivotal data for telaprevir and boceprevir, results for TMC435 and data from interferon-sparing studies.

Published By Datamonitor
13 Dec 2010 $400
Buy
Report
Report

Bydureon FDA Approval: Physician Opinion

Physician survey of 84 endocrinologists and primary care physicians on their impressions and expected use of Amylin’s and Alkermes’s Bydureon (once-weekly exenatide)

Published By Datamonitor
24 Feb 2012 $2800
Buy
Report
Report

Case Study: Autism Spectrum Disorders – Public awareness and physician detailing will drive market growth

This report examines the opportunities and threats within the autism spectrum disorders (ASDs) market. The analysis is intended to support company strategy and decision-making by providing actionable recommendations in the current treatment pathway.

Published By Datamonitor
16 Apr 2012 $1520
Buy
Report
Report

Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs

This module discusses differential pricing for antiretrovirals as a strategy that enhances access to drugs while preserving incentives for pharmaceutical companies.

Published By Datamonitor
18 May 2011 $1520
Buy
Report
Report

Case Study: Personalized Cancer Therapy - Anticipated competition threatens to dampen commercial potential of new approvals

Overview of targeted cancer therapies and biomarkers, with in-depth analysis of drug and companion diagnostic development, commercial potential, role of regulatory authorities in the seven major markets and key pipeline personalized cancer therapies.

Published By Datamonitor
16 Jul 2012 $1520
Buy
Report
Report

Case Study: Sepsis - Xigris’ disappointing performance creates a market opportunity for improved sepsis therapies

The Surviving Sepsis Campaign has created an increased focus on reducing levels of mortality from sepsis. Eli Lilly/BioCritica’s Xigris has been unable to capitalize on what remains a potentially lucrative therapy area with significant unmet needs.

Published By Datamonitor
17 May 2011 $1520
Buy
Report
Report

Central Nervous System Drug Delivery Specialists

CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel CNS treatments is to remain commercially viable.

Published By Datamonitor
05 Sep 2012 $2800
Buy
Report
Report

Commercial Insight: Disease Modification in Rheumatoid Arthritis – Market awaits game changing therapies and strategies

Coverage of disease-modifying drugs in the seven major rheumatoid arthritis markets, including indication-specific 10-year forecasts (using both sales and patient-based approaches), detailed brand profiling and an in-depth patient-based case study.

Published By Datamonitor
15 Dec 2010 $6400
Buy
Report
Report

Commercial Insight: Inflammatory Bowel Disease - Future market prospects rely on addressing cost and safety

Coverage of the inflammatory bowel disease (IBD) market, including indication-specific 10-year forecasts, detailed brand profiling, opportunities and threats, and a scenario-based case study.

Published By Datamonitor
05 Aug 2010 $15200
Buy
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.